FreshRSS

🔒
❌ Acerca de FreshRSS
☷
△ 🔃
Hay nuevos artículos disponibles. Pincha para refrescar la página.
AnteayerTus fuentes RSS

Effectiveness of vestibular incision subperiosteal tunnel access (VISTA) technique with or without A-PRF in treatment of multiple adjacent gingival recession defects (MAGRD): A 12 months CBCT study

Por: Prabhnoor Tuli · Abhay P. Kolte · Rajashri A. Kolte · Vrushali N. Lathiya · Vinisha A. Bajaj · Shahabe Saquib Abullais · Manea M. Alahmari

by Prabhnoor Tuli, Abhay P. Kolte, Rajashri A. Kolte, Vrushali N. Lathiya, Vinisha A. Bajaj, Shahabe Saquib Abullais, Manea M. Alahmari

Objectives

In order to treat MAGRD in the maxillary anterior region, the VISTA approach was evaluated and compared with and without A-PRF.

Materials and methods

A split mouth RCT was designed with 216 MAGRD that were assigned to VISTA alone and VISTA with A-PRF. The complete root coverage (CRC) and gingival thickness (GT) were measured using CBCT at baseline and 12 months post-operatively, while the clinical parameters of probing depth (PD), clinical attachment level (CAL), width of keratinized gingival (WKG), gingival recession depth (GRD), and gingival recession width (GRW) were recorded at baseline, 6 months, and 12 months.

Results

From baseline to 12 months, there was a significant decrease in the mean values of GRD and GRW with an increase in WKG. CBCT scans showed a significant increase in GT mean values. According to these results, the Test group’s CRC was higher (95.92%) than the Control groups (85.02%).

Conclusions

In contrast to the Control group, the Test group demonstrated superior MAGRD resolution in achieving a decrease in GRD and GRW as well as a higher increase in WKG and GT. These findings resulted into a substantially more CRC for the Test group.

Trial registration

Registration no. CTRI/2022/09/045845.Registered on: 26/09/2022

Diagnosing deep vein thrombosis early in critically ill patients (DETECT) trial: a protocol for a randomised controlled trial

Por: Arabi · Y. M. · Alenezi · F. · Al-Hameed · F. · al Humedi · H. I. · Kharaba · A. · Alhazzani · W. · Alshahrani · M. S. S. · Algethamy · H. · Maghrabi · K. · Chalabi · J. · Ardah · H. I. · Alahmari · A. M. · AlQahtani · R. M. · Ababtain · A. A. · Al-Filfil · W. A. M. · Al-Fares · A. A.
Introduction

Deep vein thrombosis (DVT) in critically ill patients is often undetected. However, it is unclear whether ultrasound surveillance for early detection of DVT in high-risk medical-surgical intensive care unit (ICU) patients improves patients’ outcomes. The DETECT trial (Diagnosing deep-vein thrombosis early in critically ill patients) evaluates the effect of twice-weekly bilateral lower limb ultrasound compared to usual care on 90-day mortality of critically ill adult patients admitted to medical, surgical and trauma ICUs.

 Methods and analysis

The DETECT trial is an international, parallel-group, open-label, randomised trial, which will recruit 1800 critically ill adults from over 14 hospitals in Saudi Arabia and Kuwait. Eligible patients will be allocated to twice-weekly bilateral lower limb ultrasound or usual care. The primary outcome is 90-day mortality. Secondary outcomes include lower limb proximal DVT, pulmonary embolism and clinically important bleeding. The first patient was enrolled on 21 March 2023. As of 8 April 2025, 711 patients have been enrolled from 14 centres in Saudi Arabia and Kuwait. The first interim analysis was conducted on 14 May 2025. We expect to complete recruitment by December 2026.

 Ethics and dissemination

Institutional review boards (IRBs) of each participating institution approved the study. We plan to publish the results in peer-reviewed journals and present the findings at international critical care conferences.

 Trial registration number

Clinicaltrials.gov: NCT05112705, registered on 9-11-2021.
❌